


MSY® is a knowledge-based company that was established on 2019/12/7 and started its activity as a pharmaceutical company. Based on creativity, literature and specialists opinion, a profound understanding of upgradeable points of products in our people demand, the R&D team of Mavara Salamat Yas company conducted a great number of designs to manufacture the products according to the needs of domestic consumers. After three years of round-the-clock efforts, our team have succeeded in acquiring the technical knowledge of producing cross-linked hyaluronic acid by BDDE molecule, as well as the company has produced biological molecules-based mesotherapy products - namely vitamins, amino acids, biomimetic peptides, and growth factors - that are effective in improving skin quality.

Also, this company has been planning to manufacture and supply clinically efficient oral supplements in different therapeutic areas including dermatology and orthopedics.



**Reference:**

1- Radiol Clin North Am. 2004 Jan;9-1:(1)42, v. doi: 10.1016/S1-00161(03)8389-0033. 2- Dent Clin North Am. 2014 Oct;814-797:(4)58. doi: 10.1016/j.cden.2014.07.005. Epub 2014 Aug 7 3- BMC Musculoskelet Disord. 2019 Jun 29;3(1)20;18. doi: 10.1186/s0-2667-019-12891. 4- BMC Musculoskelet Disord. 2017 May 22;2(1)18;26. doi: 10.1186/s2-1585-017-12891. 5- Am J Med. 1998 Jul 105;27(1B):31S-38S. doi: 10.1016/s2-00072(98)9343-0002. 6- Am J Med. 1998 Mar 104;30(3A):23S-29S; discussion 41S-42S. doi: 10.1016/s6-00207(97)9343-0002. 7- Polymers (Basel). 2020 Aug; 1800 : (8)12. Published online 2020 Aug 11. doi: 10.3390/polym12081800 8- ACS Biomater Sci Eng. 2015 July 493-481 : (7)1 ;13. doi:10.1021/acsbiomaterials.5b00181. 9- Meta-Analysis Cartilage. 2021 Dec;13(1\_suppl):169S-184S. doi: 19476035211021903/10.1177. Epub 2021 Jun 10. 10- <https://www.drugs.com/mtm/sodium-hyaluronate-injection.html> 11- Biomacromolecules 4354-4345 ,10 ,21 ,2020. <https://doi.org/10.1021/acs.biomac.0c01151> 12- BMC Musculoskelet Disord. 321 :16 ;2015. Published online 2015 Oct 26. doi: 10.1186/s0775-015-12891-z 13- Arthritis Res Ther. 67-54 : (2)5 ;2003. Published online 2003 Jan 14. doi: 10.1186/ar623 14- J-STAGE home/Archives of Histology and Cyto .../Volume (1998) 61 Issue 2. <https://doi.org/10.1679/aohc.61.125> 15- i2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.joca.2006.11.001



✉ info@msypharmed.com  
 🌐 msypharmed.com  
 ☎ 02191301406



# SYFLEXX<sup>®</sup> H

with Lidocaine

High Molecular Weight Sodium hyaluronate (90mg/3ml)

## High Concentration


For mild to severe osteoarthritis

- Visco-supplement
- Synovial fluid supply
- Long lasting
- Reduce wear and tear
- Reduce joint inflammation
- Pain relief
- Increase joint range of motion



STEADY STEPS

**Osteoarthritis** is a progressive, biomechanical and degenerative joint disease that leads to joint pain and movement limitation, and in more severe cases to complete disability. In the pathology of osteoarthritis, the role of immunity, metabolic changes, inflammation and cartilage destruction can be mentioned.<sup>1</sup>

**654.1M**   
people over 40 years are  
suffered from KOA Globally

**6.4M**   
people over 40 years are  
suffered from KOA in Iran

**1.69**   
Female/Men  
Prevalence Ratios

### Arthritic joints

- Have progressive damage without treatment.
- Repair is difficult due to anatomy and circulation.
- Have significantly reduction of the endogenous production of sodium hyaluronate.<sup>2-3</sup>


### Why visco-supplements injection?

- Exogenous sodium hyaluronate increases cartilage volume and type II collagen conversion.<sup>3</sup>
- Reduction of serum levels of a specific biomarker of cartilage degradation (Coll1-2) by hyaluronic acid.<sup>4</sup>
- Injection of visco-supplements has a significant effect in reducing pain and inflammation and increasing joint range of motion.<sup>3-4</sup>
- Systemic and oral drugs have high ADR.<sup>2-15</sup>
- People with OA are 2.5 to 5.5 times more likely than the general population to suffer gastrointestinal complications and be hospitalized due to the use of NSAIDs.<sup>5-6</sup>

### What is SYFLEXX® H?

- SYFLEXX® H is a intra articular visco-supplement formulated from high molecular weight (HMW) sodium hyaluronate and suitable for injection in joints suffering from osteoarthritis. (90mg/3ml)
- SYFLEXX® H is a single-use prefilled glass syringe (PFS) containing a sterile, non-pyrogenic, clear, viscoelastic, biocompatible, and biodegradable gel for intra-articular injection, produced biosynthetically.

Active ingredients	MWs	HA (%)	Lidocaine (%)	Volume
HMW sodium hyaluronate	2500-3500 KD	90 mg HA (3%)	9 ml (0.3%)	3 ml




### Why SYFLEXX® H?

- HMW sodium hyaluronate, has a high resistance to the hyaluronidase enzyme comparative LMW and MMW sodium hyaluronate.<sup>11</sup>
- long treatment period. <sup>11</sup>
- Highest hydration and ability to cover the surface of the joint, it has the most lubricating properties. <sup>11</sup>
- Prevent wear and tear, reduce inflammation, and reduce pain. <sup>11</sup>
- Restore viscosity and elasticity can improve joint range of motion.<sup>14-15</sup>

### Who can benefit from SYFLEXX® H?

Symptomatic mild to severe osteoarthritis (OA) of the knee, hip, and shoulder.



### Timeline of the 12-month course of treatment with SYFLEXX® H

